Device Trial Ads: Plan Your Strongest Patient Message Before IRB Review
In several feasibility tests run by Antidote, an 83bar company, a single ad variant generated 60% to 90% of all qualified patient leads. Every variant targeted the same patients against the same study criteria. One message simply did most of the work.
For medical device trials, that finding carries extra weight. Device studies often require a specific treatment history, a recent procedure or a measurement patients don’t know offhand. The ad that brings in the most clicks is not always the ad that brings in patients who qualify, and fewer still reach randomization.
Why device trial ad decisions matter before launch
Clinical trial recruitment ads need institutional review board (IRB) approval before patients see them. Changing recruitment copy after approval may require further IRB review before the revised version can run, creating avoidable delays. Sponsor teams that plan and evaluate their messaging early can submit stronger recruitment materials the first time.
The U.S. Food and Drug Administration (FDA) treats recruitment advertising as the start of informed consent. FDA guidance for recruitment ads covers investigational drugs, biologics and devices. Ads must not imply proven safety or effectiveness, present an investigational device as an established treatment, or mislead patients about free care. For example, an ad can’t promise “free medical treatment” when the study only means participants won’t be charged to take part.
Inside those rules, three choices separate a strong variant from a weak one.
| Choice | Volume-first Outreach | Patient Activation |
|---|---|---|
| How the ad names the condition | Whether patients recognize themselves | A clinical term versus the words patients use for their symptoms |
| Which study criteria it mentions | Who self-selects in, and who rules themselves out | Naming a required prior treatment up front, or leaving it to the screener |
| What it asks the patient to do next | How many people start, and how ready they are | A short eligibility survey versus a request to call a clinical site |
What device feasibility tests reveal
Two device-related tests from 83bar’s feasibility whitepaper show how much one criterion can change the qualified pool.
| Test | What happened |
|---|---|
| Sleep apnea device study (adults 22+, prior sleep study, prior PAP use with low success, BMI 32 or lower) | 95 survey submissions, 27 qualified, 19 very interested. 36.8% were excluded by the BMI limit alone. |
| Parkinson’s disease study requiring recent use of a specific medication delivery device | 214 survey submissions, 9 qualified. Only 4.2% reported device use in the past four months, yet 66.6% of qualified respondents were very interested. |
In both cases interest was strong, and the criteria set the ceiling. That’s why every ad variant should be checked against the screener built from the draft protocol: an ad that draws in patients the criteria will exclude only adds work for clinical site staff.
Judge the ad by randomization, not volume
Lead volume is easy to report, but it cannot tell you whether patient recruitment is progressing toward enrollment. For randomized device trials, the clearer measure is how many referred patients reach randomization. For single-arm or nonrandomized device studies, the equivalent is how many referred patients enroll.
In one cardiovascular device program, 83bar referred 15,000 patients. More than 90% of randomizations came from those referrals, and enrollment finished on time. That result depends on the whole path from ad to clinical site, which is why the message that starts it deserves early planning.
| Metric | What it tells you |
|---|---|
| Click-through rate | Whether the message stops the right people |
| Qualified rate | Whether the criteria, not the ad, limit enrollment |
| “Very interested” among qualified respondents | Whether eligible patients actually want to take part |
| Share of qualified leads per variant | Which approved message deserves more budget |
| Referral-to-randomization rate | Whether the message brings patients who finish the process |
How to plan your strongest patient message for IRB review
- Start message research before patient recruitment begins. With input from your compliance team, gather the language patients use for their condition through non-recruitment research, such as patient advisory input, concept interviews or a review of how patients describe their symptoms. This research shapes the ad copy without recruiting anyone into the clinical trial.
- Draft two or three variants that already meet FDA guidance. Change one of the three choices at a time, so the clinical trial team can see which choice made the difference.
- Check each variant against the draft protocol. Compare which study criteria each variant names with the device or treatment-history questions the screener will use to screen patients out.
- Submit the variants together in your IRB package, along with the screener logic. If the IRB approves more than one variant, the clinical trial team can compare them once patient recruitment begins, within what the IRB approved.
- Compare approved variants by qualified leads, not clicks, and shift budget toward the variant that brings in qualified, very interested patients.
Frequently asked questions
- Do device trial ads need IRB approval? Yes. Under FDA guidance, advertising for study participants, including for investigational devices, should be reviewed and approved by the IRB before use.
- Can you change a device trial ad after IRB approval? Yes, but changes to recruitment copy may require further IRB review before the revised ad can run. Review procedures vary by IRB, and some changes may qualify for an expedited process.
- Why compare ad variants if the criteria limit enrollment anyway? Testing shows which problem you have. If interest is high and qualification is low, the criteria are the constraint. If both are low, the message needs work.
Read the Full Case
83bar helps medtech sponsors move patients from first response to randomization, with digital outreach, pre-screening, a clinical contact center and site-ready referrals.

